Hypoxia, via the hypoxia-inducible factors 1 and 2 (HIF-1 and HIF-2), upregulates many genes involved in cell survival. However, proapoptotic pathways are also induced. BCL-2/adenovirus E1B-19 kDa-interacting protein 3 (BNIP3) represents a paradigm of a cell death protein that is hypoxically upregulated via HIF-1 in most cancers. We found that in contrast to many other cell types, 6/8 colorectal cancer (CRC) cell lines show little hypoxic induction of BNIP3 despite an intact HIF signalling system. Colorectal tumour tissue also loses BNIP3 expression relative to matched normal samples. Downregulation of hypoxic BNIP3 in CRC cells was independent of the expression of other BCL-2 family members, or BNIP3L. That BNIP3 plays a functional role in hypoxic survival in CRC cells was demonstrated by the fact that CRC cell lines that do not upregulate BNIP3 or have been treated with BNIP3 RNA interference were insensitive to hypoxia-induced cell death. Promoter methylation and histone deacetylation were shown to silence BNIP3 in these CRC cell lines. Of significance, hypoxic induction of BNIP3 was restored in 4/6 cell lines by trichostatin-A treatment alone. These data suggest that BNIP3 plays an important role in hypoxic cell death and epigenetic mechanisms selectively silence its expression in CRC.
Introduction
Hypoxia-inducible factor 1 (HIF-1) plays a key role in the adaptive response to hypoxia, transactivating many genes whose protein products are involved in pathways of angiogenesis, glucose metabolism and cell proliferation, thus facilitating tumour progression (Semenza, 2003) . However, it is apparent that upregulation of HIF-1 transactivates antiproliferative and proapoptotic genes (Bacon and Harris, 2004) . Regions of hypoxia are known to exist within many solid tumours and the extent of tumour hypoxia is regarded as an important prognostic factor influencing neoplastic aggression, resistance to therapy and overall patient survival (Hockel et al., 1998; Stadler et al., 1999; Knowles and Harris, 2001; Harris, 2002) . This suggests that antitumorigenic proteins that are hypoxically upregulated are either non-functional or the tumour escapes from negative signalling. In favour of the latter, p53 mutations occur in more than 50% of all human cancers (Levine, 1997) and the higher malignancy of hypoxic tumours has been attributed to the ability of hypoxia to select for cells that are more resistant to apoptosis by virtue of their acquisition of p53 mutations (Graeber et al., 1996; Yu et al., 2002) . Thus, hypoxia may be envisaged to exert pressure to select for cells that have mechanisms to silence genes contributing to pathways of cell death.
BNIP3 represents a paradigm of a cell death protein that is hypoxically upregulated via HIF-1 (Bruick, 2000; Sowter et al., 2001; Kothari et al., 2003) . BNIP3 mRNA and protein have been demonstrated to accumulate in response to hypoxia in a wide range of cell lines (Bruick, 2000; Sowter et al., 2001) . Upregulation of BNIP3 is also detected in human breast and lung tumours, where BNIP3 mRNA or protein is expressed at higher levels compared to normal tissue (Sowter et al., 2001; Giatromanolaki et al., 2004) . That BNIP3 functions as an effector of cell death has been demonstrated by overexpression of the protein in a number of cell types, including mouse embryonic fibroblasts and cardiac myocytes (Chen et al., 1997; Vande Velde et al., 2000; Kubasiak et al., 2002) . High expression of BNIP3 in ductal carcinoma in situ of the breast also correlates with high-grade necrotic lesions with invasive potential (Sowter et al., 2003) . A number of recent papers have demonstrated that methylation of the BNIP3 promoter may play an important role in silencing expression in a range of tumour types (Okami et al., 2004; Murai et al., 2005a, b) . In the current work, we confirm and extend the findings of previous studies by investigating possible mechanisms of escape from the effects of hypoxia regulation of BNIP3 in a panel of colorectal cancer (CRC) cell lines.
We found little or no hypoxic induction of BNIP3 at the protein or RNA level in the majority of them. This is in contrast to over 20 non-colonic cell lines that we have shown, hypoxically upregulate BNIP3, including the endothelial line -human umbilical vein endothelial cells (Sowter et al., 2001) . We found that CRC cell lines that do not significantly induce BNIP3 retain intact hypoxiaresponsive machinery and for the first time that downregulation is specific to BNIP3 and not general silencing of BH3 domain family members or the BNIP3 homologue BNIPL3. Histone deacetylation and DNA methylation function to silence BNIP3. Furthermore, we demonstrate that knocking out endogenous BNIP3 by RNA interference showed significant protection from hypoxia-induced cell death, suggesting that silencing of BNIP3 by epigenetic mechanisms is functionally advantageous.
These results highlight that the cell death function of BNIP3 can be escaped by silencing BNIP3 gene expression. Reactivation of a BNIP3 pathway in some CRC may be of therapeutic benefit.
Results

Effect of hypoxia on BNIP3 and BNIP3L expression in colon cell lines
We have demonstrated the hypoxic induction of BNIP3 in over 20 cell lines including those of epithelial and endothelial origin (Figure 1a ) (Sowter et al., 2001) .
We investigated the effect of hypoxia on BNIP3 in CRC cells. A panel of eight CRC cell lines were cultured under conditions of hypoxia (0.1%, O 2 ). Two of the colon cancer cell lines, CaCo2 and LS174T, showed hypoxic induction of BNIP3 comparable to that seen in non-CRC lines (Figure 1b ), but HCT116, SW620, HCA7, DLD1 and HT29 exhibited little or no hypoxic induction of BNIP3 under the same conditions (Figure 1c ). Colo-741 appeared to show BNIP3 hypoxic induction, although at a reduced level compared to LS174T and CaCo2 (Figure 1b) .
We also examined the expression of the BNIP3 homologue BNIP3L (NIP3-like protein X, NIX) in three of the CRC lines as its knockdown can promote tumour growth in p53-positive tumours (Fei et al., 2004) . However, we found no evidence of hypoxic silencing in either the p53-positive cell lines HCT116 and LS174T or the p53-negative cell line DLD1 (Figure 1d ).
BNIP3 expression in matched normal and tumour pairs
To demonstrate that loss of BNIP3 expression was not a phenomenon limited to CRC cells in culture, we evaluated a panel of 84 primary CRCs and matched normal pairs.
In 10 of the matched pairs, BNIP3 was higher in the tumour sample than in the normal (Figure 2a and b) as shown in other tumour types (Sowter et al., 2003; Giatromanolaki et al., 2004) . However, in 54 cases, BNIP3 expression was reduced in the tumour samples relative to the normal, indicating that there had been a loss of BNIP3 expression during cancer development (Figure 2c and d) . Overall, staining for BNIP3 was higher in the normal tissue compared to the tumour samples (Po0.001; Figure 2e ). We analysed the expression of BNIP3 in relation to grade in 83 of the tumour samples. Of these, 36 were well differentiated, 44 were moderately differentiated and three were poorly differentiated. A Kruskal-Wallis analysis found no significant association with BNIP3 cytoplasmic staining score and grade (P ¼ 0.575), although there was a nonsignificant decrease in BNIP3 score with increasing grade (data not shown). In addition, there was no association of BNIP3 score with Dukes stage in this cohort of tumours. Overall, this suggests that loss of BNIP3 is an early event in tumour development.
Knockdown of BNIP3 in colon cancer cells results in significant protection from cell death We evaluated the function of BNIP3 in CRC cell lines to determine whether loss of BNIP3 in the majority of CRC cell lines and tumours may be explained by selection against a negative function. We analysed the effect of hypoxia on cell death in cell line LS174T that hypoxically upregulates endogenous BNIP3 and in SW620 and HCT116 that do not hypoxically upregulate BNIP3. Cells were either untreated, mock transfected or treated with an inverted (Inv) control or BNIP3 small interfering RNA (siRNA) and the effect of hypoxia on cell death evaluated. Following 48 h exposure to normoxia or hypoxia, cells were analysed for percentage cell death using propidium iodide (PI). SW620 and HCT116 seemed largely resistant to hypoxia-mediated cell death (1.26 and 5.6% death in untreated cells in SW620 and HCT116, respectively) ( Figure 3a) . In contrast, LS174T showed significant hypoxic cell death (Po0.05; 14.1% in untreated cells) compared to the non-BNIP3-expressing lines (Figure 3a) .
Mock transfection or treatment with an Inv control siRNA did not significantly affect the levels of cell death seen under hypoxia in untreated cells (P>0.05). Transfection of LS174T cells with 20 nM BNIP3 resulted in a knockdown of hypoxically induced BNIP3 within 24 h (Figure 3b ). Knockdown of BNIP3 resulted in a 60% reduction of hypoxically induced cell death in LS174T compared to treatment with an Inv control (Po0.01) (Figure 3a ). BNIP3 siRNA had no effect on the level of hypoxic cell death in SW620 and HCT116 (data not shown).
Taken together, these results suggest that BNIP3 plays a significant role in cell death and that silencing of BNIP3 by knockdown of BNIP3 by siRNA in LS174T results in significant protection from cell death.
Effect of hypoxia on the HIF signalling pathway in colon cancer cell lines To determine whether lack of BNIP3 induction in the majority of colon cancer cell lines was owing to a general inability to respond to hypoxia, we evaluated the effect of hypoxia on the protein expression of the transcription factors HIF-1A and HIF-2A by Western blotting.
HIF-1A was hypoxically upregulated in all the CRC cell lines (Figure 4a ). HIF-2A protein levels were also increased in all colon cancer cell lines, except SW620 (data not shown) following incubation under hypoxic conditions for 16 h (Figure 4b ).
The expression of two proteins that are induced by hypoxia, glucose transporter 1 (GLUT1) and CA9 was also examined. Protein levels of GLUT1 and CA9 were clearly induced after hypoxic exposure in all lines tested ( Figure 4c ). This result showed CRC cell lines that do not hypoxically upregulate BNIP3 have an intact HIF-responsive signalling system. Effect of hypoxia on BH3 family members in CRC cell lines Previous data have suggested that hypoxia results in the downregulation of other proapoptotic BH3 domain family members, namely BAX, BID and BAD, in some CRC cell lines and that this results in enhanced survival under hypoxia (Erler et al., 2004) . We examined the hypoxic expression of BH3 family members BAX, BAD and BID in our extended CRC cell line panel to see whether hypoxia resulted in a general downregulation of BH3-only family members or whether BNIP3 expression was specifically selected against. Although the levels of BID and BAD did decrease slightly in HCT116 and the levels of BID decreased in HT29 as shown previously (Erler et al., 2004) , this was a modest reduction compared with the silencing of BNIP3 observed under hypoxia ( Figure 5 ). Furthermore, expression of BID, BAD and BAX did not decrease under hypoxia in the other colon cancer cell lines tested ( Figure 5 ).
Methylation silences the BNIP3 promoter in the majority of CRC cell lines BNIP3 contains a cytosine guanine dinucleotide (CpG) island in its promoter region and downregulation of BNIP3 by methylation has been demonstrated in a number of cancer types (Okami et al., 2004; Murai et al., 2005a, b) . We considered whether the CRC cell lines in which hypoxic BNIP3 is silenced were methylated at the promoter region. We treated all eight CRC lines with the DNA methylation inhibitor 5 0 -aza-2 0 -deoxycytidine (5aza-dC) (Figure 6a) . After a 5-day treatment with 0.1 -10 mM 5aza-dC, followed by 16 h hypoxic incubation, high levels of BNIP3 expression were restored in all of the cell lines, except HT29 (Figure 6a ). 5Aza-dC had no effect on cell lines already hypoxically upregulating BNIP3 (LS174T and CaCo2; data not shown).
Methylation-specific polymerase chain reaction (MS-PCR) was carried out to determine the methylation status of the BNIP3 promoter. Three of the six cell lines in which BNIP3 expression could be restored by 5aza-dC treatment showed promoter methylation (Figure 6b ). HT29 also appeared to be methylated (Figure 6b ). However, in two of the cell lines (Colo-741 and HCT116), MS-PCR indicated that the BNIP3 promoter was unmethylated, suggesting another mechanism or another methylated locus must be contributing to BNIP3 silencing.
Hypoxic induction of BNIP3 can be restored by treatment with an inhibitor of histone deacetylation Transcriptional silencing owing to histone deacetylase (HDAC) activity is a well-reported phenomenon in cancers (Kim et al., 2001; Suzuki et al., 2002) and HDACs are implicated in alteration of chromatin assembly and tumorigenesis.
To investigate whether the expression of BNIP3 is inactivated by HDACs, we treated all eight CRC cell lines with trichostatin-A (TSA), a specific HDAC inhibitor. After 24 h of treatment with TSA, BNIP3 protein was hypoxically induced in four of the six cell lines (Colo-741, HCA7, HCT116, SW620) that show little upregulation of BNIP3 under hypoxia (Figure 7a ). This included both cell lines that had not shown promoter methylation (Colo-741 and HCT-116) in addition to two lines that exhibit BNIP3 promoter methylation (SW620 and HCA7). TSA treatment did not further upregulate BNIP3 in LS174T and CaCo2 under hypoxia (Figure 7a ).
We evaluated BNIP3 mRNA expression after normoxic and hypoxic treatment with or without TSA, in three of the CRC cell lines: LS174T that hypoxically upregulates BNIP3, HCT116 that hypoxically upregulates BNIP3 following TSA treatment and in HT29 that shows little hypoxic induction of BNIP3 even after TSA treatment (Figure 7b ). LS174T showed a 6.7-fold increase in BNIP3 mRNA under hypoxia relative to normoxic levels. The level of expression of BNIP3 mRNA was not further increased in LS174T by TSA treatment (Figure 7b ). In contrast, HCT116 BNIP3 mRNA showed only a minor 1.6-fold increase under hypoxia, but following TSA treatment the level of BNIP3 mRNA under hypoxia increased 10.2-fold (Figure 7b ).
In HT29, BNIP3 mRNA transcript was undetectable under normoxia or hypoxia despite amplification of control gene mRNA. The mRNA analysis thus concur with the protein data.
Further analysis was made by chromatin immunoprecipitation (ChIP) assays in which antiacetylated histone H3 was used to examine the acetylation status of histone H3 in the 5 0 region of BNIP3 in LS174T, HCA7 and SW620, Colo-741 and HCT116 (Figure 7c ). ChIP assays showed that LS174T retained histone acetylation and HCA7 and SW620 had deacetylated histones supporting the TSA treatment data. Intriguingly, neither the Colo-741 nor HCT116 promoter appeared to be deacetylated at histone H3 despite the ability of TSA to restore expression of both the mRNA and protein in these cell lines (Figure 7c ).
Discussion
We have studied BNIP3 as a paradigm of a hypoxically upregulated cell death effector and have demonstrated that BNIP3 plays an integral role in contributing to hypoxic cell death. Furthermore, CRC cells can circumvent BNIP3-mediated cell death by selecting against its hypoxic upregulation. As such, silencing of BNIP3 by epigenetic mechanisms may allow colorectal tumours to adapt to the hypoxic conditions that exist within these solid cancers (Hockel and In this study, we specifically demonstrate that BNIP3 can induce hypoxic cell death in CRC cells. Colon cancer cell lines that showed little hypoxic upregulation of BNIP3 (HCT116 and SW620) were largely insensitive to hypoxia-induced cell death compared to the demonstrable detection of 15.5% hypoxic cell death in the BNIP3-expressing cell line LS174T. The cell line HCT116 has been shown previously to be insensitive to hypoxic cell death, although this was not linked to lack of BNIP3 expression (Erler et al., 2004) . We have also shown that knockdown of endogenous BNIP3 in LS174T provides significant protection from hypoxically induced cell death. Less than 100% protection from hypoxic cell death in LS174T may be attributable to incomplete knockdown of the BNIP3 protein, or the result of hypoxic induction of other functional mediators of cell death of which several have been identified including Noxa and HGTD-P (Lee et al., 2004) . Nonetheless, these functional data support the notion that hypoxic upregulation of BNIP3 in CRC cells significantly contributes to cell death.
We report that 6/8 CRC cell lines show little hypoxic upregulation of BNIP3 and that BNIP3 expression is significantly downregulated in colorectal tumours compared to matched normal tissue (Po0.001). The upregulation of BNIP3 is mediated by HIF-1 via the hypoxia-response element located within its promoter region (Bruick, 2000; Kothari et al., 2003) . However, each of the colon lines that show minimal hypoxic induction of BNIP3 have an intact HIF signalling system as demonstrated by the hypoxic induction of HIF-1 and of other HIF-1 targets, namely GLUT1 and CA9. Furthermore, normal induction of HIF-2 is also observed and these data indicate that BNIP3 inactivation occurs at a point after hypoxia-mediated HIF upregulation.
We also show that inactivation of BNIP3 is specific and not the result of general downregulation of proapoptotic BH3-only family members. BNIP3 is a member of the BH3-only subfamily of BCL-2 proteins that includes BAX, BID and BAD (Yasuda et al., 1998) . It was recently suggested that BID, BAD and BAX are hypoxically downregulated in CRC cells and play a role in the adaptation of tumour cells to a microenvironment with limited oxygen supply (Erler et al., 2004) . Although we do see downregulation of BID and BAD under hypoxia in the two cell lines analysed previously (HT29 and HCT116), the level of downregulation is modest in comparison to that of BNIP3. In addition, there is no evidence that this downregulation occurs in other CRC cell lines, whereas BNIP3 is suppressed many fold in the majority. The previous study used mainly anoxic conditions when looking at the effect of BID, BAD and BAX in hypoxic tumour growth and we do not exclude the possibility that these proapoptotic proteins have a more profound role in cell death under anoxia. However, our own data suggest selective downregulation of BNIP3 rather than a general downregulation of BH3-only proapoptotic proteins, supporting the notion that BNIP3 plays a significant role in hypoxic cell death.
We considered whether epigenetic mechanisms could contribute to BNIP3 silencing in CRC cell lines. A number of previous studies have shown that BNIP3 has a large CpG island spanning its promoter and that methylation of this region plays an important role in the transcriptional silencing of BNIP3 in a number of cancer cell types including pancreatic and gastric tumours (Okami et al., 2004; Murai et al., 2005b) . Our results agree with these studies and show that the BNIP3 promoter is methylated in half of the CRC lines that do not hypoxically upregulate BNIP3. However, our study also demonstrates the significance that histone deacetylation can have on the transcriptional status of BNIP3. Whereas previous reports have found that restoration of BNIP3 expression can be achieved by TSA treatment following pre-treatment with the demethylating agent 5aza-dC (Murai et al., 2005b) , our study shows for the first time that TSA alone can restore BNIP3 expression in CRC cell lines. In addition, histone deacetylation can be a predominant mechanism of silencing in the presence of promoter methylation as TSA alone can restore BNIP3 expression in SW620 and HCA7, which are also methylated at the BNIP3 promoter. That the cell lines Colo-741 and HCT116 did not show promoter methylation or histone deacetylation despite restoration of BNIP3 expression by 5aza-dC and TSA adds further complexity. It is possible that BNIP3 transcriptional expression is controlled from another locus in these cell lines, which is in itself epigenetically silenced. This would suggest that there are further mechanisms by which BNIP3 is silenced and underscores the notion that escape from BNIP3 function is a key requisite for CRC cells.
Our data support and add to two recent reports that find BNIP3 is silenced by DNA methylation in pancreatic and gastric cell lines (Okami et al., 2004; Murai et al., 2005b) and goes further in also highlighting a prominent role for histone de-acetylation in silencing BNIP3. Other mechanisms to by-pass the effects of BNIP3 have been shown, for example, growth factor signalling can protect against BNIP3-mediated cell death in breast cancer cell lines (Kothari et al., 2003) . There is also evidence that nuclear sequestration may act as a mechanism of BNIP3 silencing in non-small-cell lung cancer (Giatromanolaki et al., 2004) . Taken together, the data presented here along with recent studies support a model whereby hypoxic upregulation of BNIP3 in tumour development can cause significant hypoxia-induced cell death, but that this negative function provides pressure for the selection of cells that evade this phenotype. This would also suggest BNIP3 is a major contributor to hypoxia cell death.
Stepwise clonal selection within cancers is a welldocumented phenomenon (Fearon and Vogelstein, 1990; Kinzler and Vogelstein, 1996; Cahill et al., 1999; Rubin, 2001 ) and could ultimately result in a tumour cell population that is increasingly resistant to BNIP3-mediated cell death. Indeed, clinical studies have shown that BNIP3 expression is predictive of poor outcome and aggressive tumour growth (Giatromanolaki et al., 2004) . With relation to the paradox of HIF signalling, it may thus be envisaged that under hypoxia, upregulation of HIF results in the expression of genes that positively contribute to tumour growth and also those whose negative function exerts selection pressure to drive the cancer towards a more aggressive phenotype.
These results highlight the importance of histone deacetylation as another mechanism of BNIP3 silencing. Reactivation of such negative signalling pathways whose function has been escaped may provide a viable avenue of therapeutic intervention.
Materials and methods
Cell lines and tissues
Cell lines were from Cancer Research UK cell services and grown in Dulbecco's modified Eagle's medium or Rosewell's Park Memorial Institute media supplemented with 10% fetal calf serum (Sigma-Aldrich Company Ltd, Gillingham, Dorset, UK), L-glutamine (2 mM), penicillin (50 IU/ml) and streptomycin sulphate (50 mg/ml). The cell lines used were as follows: MDA-MB-468, MDA-MB-231, T47D (breast cancer), HT1080 (fibrosarcoma), LS574T, CaCo2, DLD1, HCA7, HCT116, HT29 and SW620 (CRC) .
Parallel incubations were performed on dishes of cells in normoxia (humidified air with 5% CO 2 ) or hypoxia (hypoxic conditions were generated in a Napco 7001 incubator (Precision Scientific Inc, Chicago, IL, USA) with 0.1% O 2 , 5% CO 2 and balance N 2 ).
Western blotting
Cells were homogenized in a lysis buffer containing 8 M urea, 10% sodium dodecyl sulphate (SDS), 1 M dithiothreitol and protease inhibitors. Proteins were electrophoresed on a 10% SDS-polyacrylamide gel electrophoresis gel and transferred onto a polyvinylidene difluoride membrane (Millipore (UK) Limited, Gloucestershire, UK). Proteins were detected using antibodies to BNIP3 (clone ana40, Sigma B7931), HIF-1 (BD Biosciences 610959, San Jose, CA, USA), HIF-2 (Abcam plc, Cambridge, UK, AB199), CA9 (Wykoff et al., 2000) , GLUT1 (Abcam ab652), BID (C20 Santa Cruz sc-6538, Santa Cruz Biotechnology, Santa Cruz, CA, USA), BAD (C7, Santa Cruz sc-8044) and BAX (N20 Santa Cruz sc-493) and NIX (N19, Santa Cruz sc-5860) at 1:500-1:1000. As a loading control, a mouse monoclonal antibody to b-tubulin (Sigma T4026) was used at 1:20 000. Overnight primary antibody incubation was followed by incubation with goat anti-mouse or rabbit or mouse anti-goat horseradish peroxidase (Dako, Denmark A/s, Glostrup, Denmark) and enhanced chemiluminescence developing reagents (Amersham plc, Buckinghamshire, UK). Blots were exposed to film from 30 s to 1 min. Each Western blot is representative of at least three independent experiments.
Immunostaining
Immunostaining was carried out on formalin-fixed, paraffinembedded tissue specimens from 84 primary CRCs and matched normal pairs. These were obtained from the Cellular Pathology Department, John Radcliffe Hospital, Oxford, UK. The study was approved by the Local Ethics Committee and all patients gave consent for research on tumour samples.
Briefly, 4 mm sections were dewaxed and rehydrated using standard procedure, then immunostained with BNIP3 clone Ana40 (Sigma) at a dilution of 1/500. Detection of label was performed using the Dako HRP Envision kit (Dakocytomation, Copenhagen, Denmark) as secondary as directed and diaminobenzidine.
siRNA duplexes siRNA oligonucleotides were designed following recommendations of Elbashir et al. (2002) , synthesized and purified at Eurogentec and supplied ready duplexed. BNIP3 siRNA duplex targeted nucleotides 208-227 of the BNIP3 mRNA sequence (U15174) and comprised of: sense, 5 0 -UACUGCUG GACGCACAGCAdTdT-3 0 and antisense, 5 0 -UGCAGUGC GUCCAGCAGUAdTdT-3 0 . Inv BNIP3 control duplex did not target any gene and comprised of sense, 5 0 -ACGACACG CAGGUCGUCAUdTdT-3 0 and antisense, 5 0 -AUGACGAC CUGCGUGUCGUdTdT-3 0 .
siRNA treatment of cells Cells were plated onto 10 cm 2 cell culture dishes and grown to 30-40%. The duplexes were diluted to a final concentration of 20 nM in Opti-Mem I (Invitrogen life Technologies, San Diego, CA, USA). Oligofectamine transfection reagent (25 ml) (Invitrogen Life Technologies) was added and incubated at room temperature for 25 min. The cells were incubated with the oligonucleotide duplexes in serum-free conditions for 4 h at 371C. Serum was added back to the culture, and cells were incubated for an additional 24 h before experimentation.
Cell death detection assay
Following siRNA treatment, cells were replated at 3 Â 10 5 cells/well in six-well plates in triplicate. Once attached, cells were exposed to normoxia or hypoxia for 48 h. All cells were harvested, washed and resuspended in ice-cold isoton and stained with PI (Sigma Chemical Co.). Each sample was analysed by FACScan flow cytometry (Becton Dickinson Co., Franklin Lakes, NJ, USA). Data analysis was performed with standard Cell Quest Software (Becton Dickinson Co.). Graphpad prism 4 software (Graphpad software Inc., San Diego, CA, USA) was used to calculate standard error of the mean and carry out statistical analysis using one-way analysis of variance with Bonferroni post-test to compare differences between selected data sets.
RNA extraction and reverse transcription
Extraction of total RNA from cultured epithelial cells was performed using TRI-reagent (Sigma-Aldrich, St Louis, MO, USA). RNA was treated for any contaminating DNA using DNA Free (Ambion, Austin, TX, USA). cDNA was generated from 1 mg of RNA using the High-Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA, USA).
Quantitative real-time PCR Quantitative real-time PCR (Q-RT-PCR) reactions were performed in triplicate using the Corbett Research Rotor Gene RG-300 (Sydney, Australia) and the exicon probe library system (Vedbaek, Denmark). Each reaction was made up to 25 ml containing 10 ml of cDNA template, 12.5 ml Taqman 2 Â PCR master mix (Applied Biosystems, Foster City, CA, USA), 1 ml of each primer (10 mM), 0.25 ml water and 0.25 ml specific exicon probe. PCR primers used for detection of BNIP3 were: forward, 5 0 -TGCTGCTCTCTCATTGCT-3 0 and reverse, 5 0 -GACTCCAGTTCTTCATCAAAAGGT-3 0 used with probe 22. b-Actin was used as a reference gene. b-Actin primers were: forward, 5 0 -CCCAGCACAATGAAGATCAA-3 0 and reverse, 5 0 -CGATCCACACGGAGTACTTG-3 0 used with probe 63. PCR conditions were 2 min at 501C, 10 min at 951C, and then 40 cycles each consisting of 15 s at 951C and 1 min at 601C. Reaction efficiency for each gene was calculated after obtaining standard curves by making twofold serial dilutions covering the range 40-1.25 ng of RNA. Relative quantification of gene expression was performed using the method described by Pfaffl (2001) .
TSA treatment and hypoxic exposure CRC cell lines were seeded at 1 Â 10 6 cells/10 cm dish in culture medium in triplicate. TSA (Sigma) was added to the attached cells at final concentrations of 0.1, 0.5 or 1 mM and the cells allowed to grow for 24 h. Untreated controls were prepared in parallel. After treatment, cells were exposed to normoxia or hypoxia as described above (0.1% O 2 , 5% CO 2 ) for a further 16 h. RNA and protein were extracted for protein analysis and RT-PCR.
Chromatin immunoprecipitation
ChIP assays were carried out as described previously (Magdinier and Wolffe, 2001 ) using a ChIP assay kit (Upstate Biotechnologies, Lake Placid, NY, USA). PCR was carried out using BNIP3 ChIP primers as described previously (Murai et al., 2005b) . PCRs were carried out in triplicate on duplicate independent samples. 5Aza-dC treatment and hypoxic exposure CRC cell lines HT29 and HCT116 were seeded at 5 Â 10 6 cells/ 10 cm dish in culture medium in triplicate. 5Aza-dC (Sigma) was added to attached cells at final concentrations of 0.1, 1 or 10 mM and the cells allowed to grow for 5 days. Untreated controls were prepared in parallel. After treatment, cells were exposed to normoxia or hypoxia as described above (0.1% O 2 , 5% CO 2 ) for a further 16 h and protein was extracted for analysis.
Genomic DNA Isolation and bisulphite treatment of DNA Genomic DNA was extracted from CRC lines using Dneasy (Qiagen Ltd, Crawley, UK) based on the manufacturer's protocol. CpG conversion was carried out using a CpGenome DNA modification Kit (Serologics Corp., Norcross, GA, USA) according to the manufacturer's instructions. After this treatment, unmethylated cytosine is converted to uracil, whereas methylated cytosine remains cytosine.
MS-PCR
MS-PCR was performed according to the previously described principles (Herman et al., 1996) and using the primers and reaction conditions described previously (Okami et al., 2004) . Each PCR was carried out in triplicate on duplicate independent samples.
